Mapping Brain Structure and Function in AD

描述（由申请人提供）：这是独立科学家职业发展奖（K02）申请“AD中的脑结构和功能映射”的重新提交，旨在加强申请人对神经退行性过程，痴呆和用于评估和监测功能损伤的神经心理学测量的理解。K02活动将使候选人获得最先进的结构神经成像方法的技能，将临床知识与定量专业知识相结合，并开发更有用的临床神经成像方法。申请人是匹兹堡大学放射学和生物统计学研究副教授，PET方法学主任。候选人将大量时间投入到方法论服务计划中，K02奖将保护申请人获得新的和当前的研究知识的关键时间，支持她追求独立的小说研究，同时促进合作研究的互动。申请人的主要研究专长是评估配体结合相互作用、血流和葡萄糖代谢的PET成像新方法。该候选人的独立研究旨在：1)利用淀粉样蛋白结合放射性示踪剂Pittsburgh Compound-B或PIB，确定一种简单有效的PET方法，用于在体内评估阿尔茨海默病（AD）的淀粉样蛋白沉积（R01 MH070729, 2004-7）；2)测量伴有和不伴有抑郁症的2型糖尿病（非胰岛素依赖型）患者的血流量和血清素神经受体系统功能（K01 MH001976, 2001-6）。K02活动将基于淀粉样蛋白成像R01研究以及她作为淀粉样蛋白成像项目的成像、方法学和统计核心主任所进行的相关研究，该项目将把PIB PET成像扩展到纵向研究和非ad痴呆（P01 AG025204, PI: S. DeKosky， M.D, 2005-10）。K02活动与候选人的长期目标一致，即开发综合神经成像方法，可以利用多种类型的受试者内部信息（例如结构MR，功能PET，行为测量），以提供临床信息更丰富的稳健结果测量，与她的指导职业发展奖（K01）的主题一致，这是最后一年。

DESCRIPTION (provided by applicant): This is a resubmission of an Independent Scientist Career Development Award (K02) application ""Mapping Brain Structure and Function in AD", that is designed to strengthen the applicant's understanding of neurodegenerative processes, dementia, and the neuropsychological measures that are used to assess and monitor functional impairment. The K02 activities will enable the candidate to acquire skills in state-of-the-art structural neuroimaging methods, integrate clinical knowledge with quantitative expertise, and develop neuroimaging methods that are more clinically useful. The applicant is Research Associate Professor of Radiology and Biostatistics and Head of PET Methodology, at the University of Pittsburgh. The candidate devotes considerable time to methodology service initiatives and the K02 award would protect critical time for the applicant to acquire new and current research knowledge, support her pursuit of independent novel research, while fostering collaborative research interactions. The applicant's primary research expertise is in the evaluation of novel methods for PET imaging of ligand-binding interactions, blood flow, and glucose metabolism. The candidate's independent research is aimed to: 1) determine a simple and valid PET method for the in vivo assessment of amyloid deposition in Alzheimer's disease (AD) using the amyloid- binding radiotracer, Pittsburgh Compound-B, or PIB (R01 MH070729, 2004-7); and 2) measure blood flow and serotonin neuroreceptor system function in subjects with Type 2 diabetes (non-insulin-dependent), with and without concomitant depression (K01 MH001976, 2001-6). The K02 activities will be based upon the amyloid-imaging R01 research and related research conducted in her role as Director of the Imaging, Methodology, and Statistics Core for the amyloid-imaging program project that will extend PIB PET imaging to longitudinal studies and non-AD dementia (P01 AG025204, PI: S. DeKosky, M.D., 2005-10). The K02 activities are consistent with the candidate's long-term goal that is to develop comprehensive neuroimaging methods that can utilize multiple types of intra-subject information (e.g. structural MR, functional PET, behavioral measures) to provide robust outcome measures that are clinically more informative, consistent with the theme of her mentored career development award (K01) that is in its final year.